Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension

Three studies comprise this OM5 Program

• Study OM5 / LOV111859 (double-blind study) and OM5X / LOV111860 (1st open-label extension) are part of this listing on ClinicalTrials.gov - NCT00246636.
• Study OM5XX / LOV111821 (2nd open-label extension) is listed as a separate listing on ClinicalTrials.gov - NCT00891293

For OM5/LOV111858 -

Inclusion criteria

• Men and women ages 18-79 years, inclusive
• Triglyceride levels between 500 mg/dL and <1300 mg/dL
• Body mass index between 25 and 43 kg/m2
• Willingness to follow a low-saturated fat diet during the study period and maintain current physical activity level
• Normally active and in good health on the basis of medical history, brief physical examination, electrocardiogram, and routine laboratory tests
• Provide written informed consent and authorization for protected health information disclosure

Exclusion criteria

• Sensitivity to fibrate drugs or omega-3 fatty acids
• Lipoprotein lipase impairment or apo C-2 deficiency or Type III hyperlipidemia
• History of pancreatitis
• Recent history of certain kidney, liver, lung, or gastrointestinal disease or cancer (except non-melanoma skin cancer)
• Poorly controlled diabetes mellitus
• Type 1 diabetes
• Pregnant or lactating females. Women of childbearing potential who are not using a medically approved method of contraception.
• Use of certain types of hormones, anticonvulsant drugs, immunologic drugs, antibiotic, antifungal and antiviral drugs, and cardiac drugs
• Use of isotretinoin (Accutane)
• Use of warfarin (Coumadin)

For OM5X/LOV111859 -

Subjects were included in the study if they met the following criteria:

• Satisfied all inclusion and exclusion criteria prior to and throughout the previous OM5 study or had a corresponding approved protocol deviation
• Successfully completed the previous OM5 double-blind study to Week 8
• Provided written informed consent on or before the Week 8 clinic visit of the OM5 double-blind study (i.e., Visit 1X of the OM5X extension study)